logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Genzyme Corporation drugs

    FiltersReset Filters
    17 results

    • aldurazyme

      (laronidase)
      Genzyme Corporation
      Usage: ALDURAZYME® is indicated for treating adults and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), as well as those with moderate to severe symptoms of the Scheie form. Its safety for mildly affected Scheie patients and CNS effects are not established.

    • aubagio

      (teriflunomide)
      Genzyme Corporation
      Usage: AUBAGIO® is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • cablivi

      (caplacizumab)
      Genzyme Corporation
      Usage: CABLIVI is indicated for treating adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), used alongside plasma exchange and immunosuppressive therapy.

    • campath - alemtuzumab injection

      (Alemtuzumab)
      Genzyme Corporation

    • caprelsa

      (Vandetanib)
      Genzyme Corporation
      Usage: CAPRELSA is indicated for treating symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It may be used cautiously in patients with indolent, asymptomatic, or slowly progressing disease after weighing treatment-related risks.

    • cerdelga

      (eliglustat)
      Genzyme Corporation
      Usage: CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are categorized as extensive, intermediate, or poor CYP2D6 metabolizers, as determined by an FDA-cleared test. Limitations apply for ultra-rapid metabolizers and indeterminate genotypes.

    • cerezyme

      (IMIGLUCERASE)
      Genzyme Corporation
      Usage: Cerezyme is indicated for the treatment of adults and children aged 2 years and older with Type 1 Gaucher disease, addressing conditions such as anemia, thrombocytopenia, bone disease, and hepatomegaly or splenomegaly.

    • fabrazyme

      (AGALSIDASE BETA)
      Genzyme Corporation
      Usage: FABRAZYME® is indicated for the treatment of adult and pediatric patients aged 2 years and older who have confirmed Fabry disease.

    • lemtrada

      (ALEMTUZUMAB)
      Genzyme Corporation
      Usage: LEMTRADA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting and active secondary progressive disease. It is recommended for patients who have not responded adequately to two or more MS treatments. It is not recommended for clinically isolated syndrome (CIS).

    • lumizyme

      (ALGLUCOSIDASE ALFA)
      Genzyme Corporation
      Usage: LUMIZYME® is indicated for the treatment of Pompe disease, which is characterized by acid α-glucosidase (GAA) deficiency.